Posted by Michael Wonder on 27 Jul 2017
'We have been waiting for this moment for so long': hepatitis C patients have access to cure with Epclusa PBS listing
28 July 2017 - More than 200,000 Australians with hepatitis C will soon be able to afford a new, highly effective treatment for the chronic, highly stigmatised infection.
From August 1, the Turnbull government will subsidise the drug Epclusa, a bumper medication combining the two antivirals sofosbuvir and velpatasvir, Health Minister Greg Hunt is set to announce on Friday.
The PBS listing means patients will pay a maximum $38.80 a month ($6.30 for concession patients) for the medication that would otherwise cost over $20,000 per treatment.
